Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Batoclimab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HanAll’s Batoclimab gets Japan Orphan Drug Status for Thyroid Eye Disease
Details : IMVT-1401 (batoclimab) is an anti-FcRn antibody candidate, which is being evaluated for the treatment of active thyroid eye disease.
Product Name : IMVT-1401
Product Type : Antibody
Upfront Cash : Inapplicable
March 06, 2025
Lead Product(s) : Batoclimab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HanAll, Daewoong and NurrOn Complete First Human Parkinson’s Therapy Study
Details : HL192(ATH-399A) is a first-in-class small molecule that focuses on activating Nurr1, it is being investigating for treating Parkinson's Disease.
Product Name : HL192
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 25, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Discovery Platform
Sponsor : Turn Biotechnologies
Deal Size : $300.0 million
Deal Type : Licensing Agreement
HanAll Signs Licensing Agreement with Turn Biotechnologies for Eye and Ear Treatments
Details : The collaboration aims to leverage HanAll's extensive expertise in ophthalmic and otic diseases and Turn Bio's cellular reprogramming technology to create innovative therapies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 28, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery Platform
Sponsor : Turn Biotechnologies
Deal Size : $300.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Tanfanercept
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HanAll Biopharma Begins Phase 3 VELOS-4 Trial for Tanfanercept in Dry Eye Disease
Details : HK036 (tanfanercept) is a potentially first-in-class topical anti-inflammatory treatment targeting tumor necrosis factor (TNF). It is being evaluated for the treatment of dry eye disease.
Product Name : HL036
Product Type : Protein
Upfront Cash : Inapplicable
March 05, 2024
Lead Product(s) : Tanfanercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HL192 (ATH-399A) is a first-in-class small molecule that focuses on activating Nurr1, a master regulator associated with the development and maintenance of dopaminergic neurons, for the potential treatment of Parkinson's Disease.
Product Name : HL192
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2023
Lead Product(s) : Batoclimab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Nona Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IMVT-1401 (batoclimab) is a fully human, subcutaneously administered antibody originated from HanAll, which selectively binds to and inhibits the neonatal Fc receptor (FcRn). It has demonstrated high potential as a new treatment option for gMG patients.
Product Name : IMVT-1401
Product Type : Antibody
Upfront Cash : Inapplicable
June 03, 2023
Lead Product(s) : Batoclimab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Nona Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tanfanercept
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Daewoong Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HL036 (tanfanercept) is a novel, potentially first-in-class topical anti-inflammatory treatment targeting tumor necrosis factor alpha for the treatment of dry eye disease, co-developed with Daewoong Pharmaceutical.
Product Name : HL036
Product Type : Protein
Upfront Cash : Inapplicable
May 19, 2023
Lead Product(s) : Tanfanercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Daewoong Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IMVT-1402
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Immunovant
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402). In animal studies, HL161ANS indicated deep IgG reductions similar to batoclimab with no or minimal impact on albumin and LDL c...
Product Name : IMVT-1402
Product Type : Antibody
Upfront Cash : Inapplicable
May 10, 2022
Lead Product(s) : IMVT-1402
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Immunovant
Deal Size : Inapplicable
Deal Type : Inapplicable